Providers increasingly encounter patients Read More Protecting Muscle While Treating Obesity: New Protein Targets for Older Adults on GLP-1s Jun 16, 2026 Articles, Diet and Nutrition, Exercise, Geriatric Medicine, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Obesity, Obesity 1,609 views The rise of highly effective GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment
Mert I, Cetinkaya A, Gurler M, Turel CA, Celik H, Torun IE et al (2022) Anti-inflammatory potential of liraglutide, a glucagon-like peptide-1 receptor agonist, in rats with peripheral acute inflammation
Bioavailability determines what percentage of the injected dose actually reaches systemic circulation
A., & Hamed, A
Why this approval matters Saxenda was the first GLP-1 drug approved to help with weight loss in the U.S., originally approved in December 2014